Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: A randomized clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 1, 2002, Pages 122-128

  Andersson, Björn ^a,c   Johannsson, Gudmundur ^b   Holm, Goran ^a   Bengtsson, Bengt Ake ^b   Sashegyi, Andreas ^a   Pavo, Imre ^a   Mason, Timothy ^b   Anderson, Pamela W ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET THERAPY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0036148237     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.1.8168     Document Type: Article

References (53)

1. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
2. Molecular determinants of tissue selectivity in estrogen receptor modulators
3. Effects of raloxifene and hormone replacement therapy on markers of inflammation in healthy postmenopausal women
4. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
5. Diabetes mellitus and the incidence of hip fracture: Results from the Nord-Trondelag Health Survey
6. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo study
7. Diabetes mellitus and cardiovascular disease in women
8. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology
9. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes
10. Testosterone concentrations in women and men with NIDDM
11. Relationship of sex hormone-binding globulin to lipid, lipoprotein, glucose, and insulin concentrations in postmenopausal women
12. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-Yr follow-up of population study of women in Gothenburg, Sweden
13. Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men
14. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: Evidence for in vivo biological activity
15. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update
16. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus
17. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
18. Glycated haemoglobin: An assessment of high capacity liquid chromatographic and immunoassay methods
19. Glucose clamp technique: A method for quantifying insulin secretion and resistance
20. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: Executive summary
21. A critical evaluation of simple methods for the estimation of free testosterone in serum
22. Radioimmunoassays for IGFs and IGFBPs
23. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: Predictive equations
24. Effects of the selective estrogen receptor modulator raloxifene on IGF1-GH and insulin-glucose homeostasis
25. Effect of 17β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus
26. The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women
27. Lipoproteins and low-dose estradiol replacement therapy in post-menopausal type 2 diabetic patients: The effect of addition of norethisterone acetate
28. The effects of hormone replacement therapy on plasma lipids in type II diabetes
29. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial
30. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
31. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?
32. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health study
33. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
34. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: A common endocrinopathy with distinct pathophysiologic features
35. The gonadotropic function of insulin
36. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin
37. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome
38. Relationship between insulin sensitivity and circulating sex hormone-binding globulin levels in hyperandrogenic obese women
39. Anthropometric variables and metabolism in polycystic ovarian disease
40. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome
41. Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome
42. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer
43. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients
44. Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids
45. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women
46. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women
47. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer
48. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice
49. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex
50. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women